The Overlooked Reason Why I Think Gilead Sciences Remains Undervalued

The Overlooked Reason Why I Think Gilead Sciences Remains Undervalued

Management's ability to buy companies with great drugs could result in solid returns in the future. more »

Fool Wire

  • Industry Focus: An update on the Greek financial crisis, an unconventional lending strategy, and what to expect in quarterly earnings. (link) added 53 minutes ago by TMFKlesta

  • Market Foolery: Greek voters deliver a resounding “no,” and Weight Watchers International gains on activist news. (link) added 54 minutes ago by TMFKlesta

  • Industry Focus: Celgene hands $1B to Juno Therapeutics, and health insurance on the exchanges will climb 4.4% next year. (link) added 4 days ago by TMFKlesta


Advertisement